US patents for Nicox' Vyzulta eligible for term extension

22 April 2021

The US Patent and Trademark Office (USPTO) has determined that three US composition of matter patents covering latanoprostene bunod, commercialized as Vyzulta, (latanoprostene bunod ophthalmic solution), 0.024%, are eligible for patent term extension, potentially through to 2030, says French eye-care specialist Nicox (Euronext Paris: COX).

The initial patent term of the latanoprostene bunod patents concerned is 2025. Nicox believes that each of these patents could be extended by almost the maximum five years allowable. The duration of this patent extension is subject to calculation by the US Food and Drug Administration with the final decision of the USPTO regarding the term of the extension expected in two to three years. Nicox would then select one of the three patents for the extension.

Vyzulta is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Patent extension will ensure long-term revenue source

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK